RASP and Immune Mediated Disease Interview with John Sheppard, MD, MMsc, President of Virginia Eye Consultants. Join us as we dive into the deep with Dr. Sheppard on the topic of inflammatory dry eye. The future of anti-inflammatory dry eye therapy is more than the T-Cell response. Dr. Sheppard gives us his perspectives on RASP (reactive aldehyde species) inhibitors, and Acthar (corticotropin) injections as potential dry eye therapies of the future.
RASP and Immune Mediated Disease Interview with John Sheppard, MD, MMsc, President of Virginia Eye Consultants. Join us as we dive into the deep with Dr. Sheppard on the topic of inflammatory dry eye. The future of anti-inflammatory dry eye therapy is more than the T-Cell response. Dr. Sheppard gives us his perspectives on RASP (reactive aldehyde species) inhibitors, and Acthar (corticotropin) injections as potential dry eye therapies of the future.
